Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02019550 · ClinicalTrials.gov registry record · Phase 4
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase 4 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 4
- Development phase
- 97
- Enrollment target
NCT02019550 is a Phase 4 study that has completed, run by EMD Serono. The registered enrollment target is 97 participants.
The verdict
NCT02019550, a Phase 4 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 97 participants
- Enrollment target
Study Summary
This is a Phase 4, prospective, open-label, randomized, cross-over, multicenter trial to evaluate ease-of-use with Rebif® Rebidose® and Rebiject II® autoinjectors in subjects with relapsing remitting multiple sclerosis (RRMS). Subjects will participate in the study for up to 10 weeks (including screening and treatment periods). The treatment period will last 8 weeks and include 12 self-injections using the Rebif® Rebidose® device and 12 self-injections using the Rebiject II® device.
Interventions
- DEVICE Rebif Rebidose
- DEVICE Rebiject II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02019550
The ClinicalTrials.gov registry entry for NCT02019550 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rebif Rebidose is the first listed.
NCT02019550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02019550 about?
NCT02019550 is a clinical study titled "Rebif® Rebidose® Versus Rebiject II® Ease-of-Use". This is a Phase 4, prospective, open-label, randomized, cross-over, multicenter trial to evaluate ease-of-use with Rebif® Rebidose® and Rebiject II® autoinjectors in subjects with relapsing remitting multiple sclerosis (RRMS). Subjects will participate in the study for up to 10 weeks (including scre...
What is the current status of trial NCT02019550?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 97 participants. The study started on 2014-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02019550?
The interventions under investigation include: Rebif Rebidose (DEVICE), Rebiject II (DEVICE).
Who is sponsoring clinical trial NCT02019550?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.